MBX Biosciences, Inc. Operating Expenses
MBX Biosciences, Inc. (MBX) reported Operating Expenses of $40.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- MBX Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $40.93M, a 87.71% increase year-over-year.
- MBX Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $27.27M, a 2.77% increase year-over-year.
- MBX Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $25.80M, a 38.61% increase year-over-year.
- MBX Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $23.93M, a 22.00% increase year-over-year.
- MBX Biosciences, Inc. operating expenses for fiscal 2025 was $98.06M, a 43.79% increase from fiscal 2024.
- MBX Biosciences, Inc. operating expenses for fiscal 2024 was $68.19M, a 93.12% increase from fiscal 2023.
- MBX Biosciences, Inc. operating expenses for fiscal 2023 was $35.31M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.93M 10-Q · filed 2026-08-06 | $68.20M 10-Q · filed 2026-08-06 | $93.99M derived: sum of 3 quarters · filed 2026-08-06 | $117.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $27.27M 10-Q · filed 2026-05-07 | $53.06M derived: sum of 2 quarters · filed 2026-05-07 | $76.99M derived: sum of 3 quarters · filed 2026-05-07 | $98.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $25.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $49.72M derived: sum of 2 quarters · filed 2026-03-12 | $71.53M derived: sum of 3 quarters · filed 2026-08-06 | $98.06M 10-K · filed 2026-03-12 |
| 2025-09-30 | $23.93M 10-Q · filed 2025-11-06 | $45.73M derived: sum of 2 quarters · filed 2026-08-06 | $72.26M 10-Q · filed 2025-11-06 | $90.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.80M 10-Q · filed 2026-08-06 | $48.33M 10-Q · filed 2026-08-06 | $66.94M derived: sum of 3 quarters · filed 2026-08-06 | $86.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $26.53M 10-Q · filed 2026-05-07 | $45.14M derived: sum of 2 quarters · filed 2026-05-07 | $64.75M derived: sum of 3 quarters · filed 2026-05-07 | $81.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $38.22M derived: sum of 2 quarters · filed 2026-03-12 | $54.88M derived: sum of 3 quarters · filed 2026-03-12 | $68.19M 10-K · filed 2026-03-12 |
| 2024-09-30 | $19.61M 10-Q · filed 2025-11-06 | $36.27M derived: sum of 2 quarters · filed 2025-11-06 | $49.58M 10-Q · filed 2025-11-06 | $59.58M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $16.66M 10-Q · filed 2025-08-07 | $29.97M 10-Q · filed 2025-08-07 | $39.96M derived: sum of 3 quarters · filed 2025-08-07 | $50.91M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $13.31M 10-Q · filed 2025-05-12 | $23.30M derived: sum of 2 quarters · filed 2025-05-12 | $34.25M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $20.94M derived: sum of 2 quarters · filed 2025-03-17 | $35.31M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $10.95M 10-Q · filed 2024-11-07 | $25.32M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |